Although the effects of antihistamines do not trump other treatments, adding oral fexofenadine to the topical treatment for AD led to the conclusion that combined treatment significantly lowers serum IL-31 levels in patients [34]. This evidence concerns the gene IL31 and Alzheimer disease.